LaserOptics announced on the 21st that it has signed a memorandum of understanding (MOU) with JSK Biomed to strengthen the product competitiveness of the needle-free drug delivery system (Microjet Drug Delivery System) ‘Mirajet’ and expand its presence in the global market.
MiraJet, the world's first needle-free drug delivery system developed by JSK Biomed, is being built in partnership with Laseroptek's Er:YAG laser technology, the LOTUS III, to be provided together with domestic hospitals and clinics. This system utilizes a 2940nm wavelength laser beam, which is highly absorbent in water, to instantly create high pressure and deliver liquid medicine to the skin in a fine jet.
Through this agreement, the two companies plan to strengthen cooperation in various areas, including ▲enhancing the existing Mirajet product, ▲jointly developing a next-generation needle-free drug delivery system, ▲jointly establishing a strategy to enter overseas markets, ▲entering the market for related consumables such as skin boosters, and planning new businesses.
A LaserOptec official stated, “Laser-based needle-free drug delivery technology has significant potential as its application is expanding not only in beauty but also across the medical and regenerative fields.” He added, “Through this agreement, we will lead the market by strengthening the competitiveness of existing products and accelerating the development of next-generation drug delivery systems.”
- See more related articles
You must be logged in to post a comment.